The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2016 | Myeloma 2016: Panel discussion on the new treatment paradigm
The Myeloma 2016 meeting, was held in Boston, MA, from 22–24 April. Keith Stewart MB, ChB from the Mayo Clinic, discusses the day 2 highlights with Kenneth Anderson, MD of the Dana-Farber Cancer Institute, Gareth Morgan, MD, FRCP, FRCPath of the UAMS Myeloma Institute, and Jésus San Miguel of the University of Navarra. Here the experts discuss the use of immunomodulatory drugs (IMiDs), and a new class of drugs called degronimids; targeted therapies, immunotherapies and minimum residual disease (MRD).
